Ms Rita P O'malley, MA, LDT/C in Belford, NJ - Psychologist

Ms Rita P O'malley, MA, LDT/C is a Psychologist - School based in Belford, New Jersey. Ms Rita P O'malley is licensed to practice in New Jersey (license number STUDENT) and her current practice location is 417 Church St, Belford, New Jersey. She can be reached at her office (for appointments etc.) via phone at (732) 284-0619.

NPI number for Ms Rita P O'malley is 1497921878 and her current mailing address is 417 Church St, Belford, New Jersey. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1497921878.

Contact Information

	Ms Rita P O'malley, MA, LDT/C
	417 Church St, Belford, NJ 07718-1057
	(732) 284-0619
	(732) 495-3627

Healthcare Provider's Profile

Full Name	Ms Rita P O'malley
Gender	Female
Speciality	Psychologist - School
Location	417 Church St, Belford, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1497921878
Provider Enumeration Date: 05/05/2008
Last Update Date: 10/13/2015

Medical Identifiers

Medical identifiers for Ms Rita P O'malley such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1497921878	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TS0200X	Psychologist - School	STUDENT (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Rita P O'malley is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Rita P O'malley, MA, LDT/C 417 Church St, Belford, NJ 07718-1057 Ph: (732) 284-0619	Ms Rita P O'malley, MA, LDT/C 417 Church St, Belford, NJ 07718-1057 Ph: (732) 284-0619

News Archive

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Maintaining periodontal health may contribute to a healthy respiratory system, according to research published in the Journal of Periodontology. A new study suggests that periodontal disease may increase the risk for respiratory infections, such as chronic obstructive pulmonary disease (COPD) and pneumonia.

Gene signature explains why 18F-FDG imaging performs better for PSMA-suppressed prostate cancer patients

Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).

Open access to large-scale drug discovery data

The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL's European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain.

New strategy allows long-term, non-invasive tracking of cardiomyocytes

A new platform reported on today in STEM CELLS Translational Medicine (SCTM) will enable long-term tracking of cardiomyocytes produced from induced pluripotent stem cells (iPSCs) after implantation into the heart.

Ms Rita P O'malley, MA, LDT/C - Psychologist in Belford, NJ